Labcorp Completes Acquisition of Millennium Health

November 4, 2026

Acquisition aims to expand toxicology testing access nationwide and provide clinical insights to support patients living with chronic pain, substance use disorders and mental health challenges

BURLINGTON, N.C., Nov. 4, 2026 – Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announces it has completed its acquisition of Millennium Health, an accredited specialty laboratory with more than 15 years of experience in drug testing and surveillance.

Millennium Health provides critical insights into patients' recent use of prescription medications and/or illicit drugs, helping clinicians more effectively monitor and treat individuals living with chronic pain, substance use disorders, mental health conditions and other health needs.

"The completion of this acquisition marks an important step in strengthening Labcorp's toxicology capabilities and expanding access to these important testing services for patients across the country," said Andrea Throop, Ph.D., Head of Toxicology at Labcorp. "By bringing together Labcorp's national scale, scientific expertise and digital capabilities with Millennium Health's deep experience in toxicology testing and drug surveillance, we are well positioned to support healthcare providers with actionable information that helps improve patient care and outcomes."

Upon integration, patients, clinicians and Millennium customers are expected to benefit from Labcorp's extensive test menu, patient service center (PSC) network of convenient locations across the U.S. and leading digital solutions to assist with test ordering and result delivery.

Hogan Lovells Cadwalader served as legal counsel for Labcorp, and Blank Rome served as legal counsel for Millennium Health.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the anticipated benefits to physicians, patients and customers of the transaction between Millennium Health and Labcorp, including broader access to toxicology services, Labcorp's extensive test menu and patient service center network and digital solutions to support test ordering and result delivery, as well as how the transaction will further support Labcorp's business strategies.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond Labcorp's control. These factors, in some cases, have affected and in the future (together with other factors) could affect Labcorp's ability to implement its business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

Labcorp has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in Labcorp's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in subsequent quarterly reports on Form 10-Q and its other filings with the SEC. The information in this press release should be read in conjunction with a review of Labcorp's filings with the SEC including the information in its most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".

Media
Racquel White
Media@Labcorp.com

Investors
Nickolo Russo
Investor@Labcorp.com